Table 2.
Parasitological and clinical outcomes of enrolled patients
| Outcome | Kibaha (n = 83) | Mlimba (n = 85) | Mkuzi (n = 88) | Ujiji (n = 88) | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) | 95%CI | n (%) | 95%CI | n (%) | 95%CI | n (%) | 95%CI | |
| PCR Uncorrected | ||||||||
| ETF | 0 | – | 0 | – | 0 | – | 0 | – |
| LCF | 8 (9.6) | 4.9–18.2 | 3 (3.5) | 1.1–10.5 | 8 (9.1) | 4.6–17.2 | 6 (6.8) | 3.1–14.5 |
| LPF | 4 (4.8) | 1.8–12.2 | 9 (10.6) | 5.6–19.2 | 23 (26.1) | 18–36.4 | 17 (19.3) | 12.3–29 |
| ACPR | 71 (85.5) | 76.1–91.6 | 73 (85.9) | 76.7–91.8 | 57 (64.8) | 54.2–74.1 | 65 (73.9) | 63.6–82 |
| Total | 83 | 85 | 88 | 88 | ||||
| Excluded | ||||||||
| Withdrawn/lost | 2 | 3 | 0 | 0 | ||||
| Cumulative cure rate | 85.6 | 76.0–91.5 | 85.9 | 76.5–91.7 | 64.8 | 53.8–73.7 | 73.9 | 63.3–81.8 |
| PCR Corrected | ||||||||
| ETF | 0 | – | 0 | – | 0 | – | 0 | – |
| LCF | 1 (1.4) | 0.2–9.4 | 0 | – | 0 | – | 0 | – |
| LPF | 1(1.4) | – | 0 | – | 1 (1.7) | 0.2–11.5 | 1 (1.5) | 0.2–10.2 |
| ACPR | 71 (97.3) | 90.6–99.8 | 73 (100) | – | 57 (98.3) | 88.5–99.8 | 65 (98.5) | 89.8–99.8 |
| Total | 73 | 73 | 58 | 66 | ||||
| Excluded | ||||||||
| Reinfections | 10 | 11 | 28 | 21 | ||||
| PCR unknown | 0 | 1 | 1 | 1 | ||||
| Missing PCR | 0 | 0 | 1 | 0 | ||||
| Withdrawn/lost | 2 | 3 | 0 | 0 | ||||
|
Cumulative cure rate (Kaplan–Meier) |
97.6 | 90.5–99.4 | 100 | - | 98.6 | 90.7–99.8 | 98.8 | 91.9–99.8 |
ETF Early Treatment Failure, LPF Late Parasitological Response, LCF Late Clinical Failure, ACPR Adequate Clinical and Parasitological Response